To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Tetrabenazine is a drug for the symptomatical treatment of hyperkinetic movement disorder and is marketed under the trade names Nitoman® in Canada and Xenazine® in New Zealand and some parts of Europe, and is also available in the USA as an orphan drug. On December 6, 2007 an advisory committee to the U.S. Food and Drug Administration (FDA) voted unanimously to recommend the approval of tetrabenazine, which would be the first drug approved in the United States to treat chorea associated with Huntington disease (HD). The compound is known since the 1950s. Tetrabenazine works mainly as a VMAT-inhibitor and as such promotes the early metabolic degradation of the neurotransmitter dopamine.
Additional recommended knowledge
Tetrabenazine is used as a treatment, but not a cure for hyperkinetic disorders such as:
Because tetrabenazine is closely related to the antipsychotics, many of its side effects are similar. Some of these include:
Unlike many of the antipychotics, tetrabenazine is not known to cause Tardive dyskinesia, and in fact can be an effective treatment for the antipsychotic-induced movement disorder.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Tetrabenazine". A list of authors is available in Wikipedia.|